Literature DB >> 1845171

Classification of aberrant crypt foci and microadenomas in human colon.

L Roncucci1, A Medline, W R Bruce.   

Abstract

Aberrant crypt foci (ACF) can be observed and quantified on the mucosal surface of formalin-fixed human colon resections after staining with methylene blue. To determine whether these ACF could be identified in fresh tissue, 10 colon resections were collected after surgery for colorectal cancer. Unfixed and fixed flat normal colonic mucosa from each colon were scored for ACF under a dissecting microscope after methylene blue staining. The number of ACF per cm2 and the average number of crypts per foci correlated highly in unfixed and fixed mucosa (r = 0.93 and 0.78, respectively). A significantly higher frequency of lesions was found in left-sided compared to right-sided colon resections. To determine whether the topographic features of the ACF gave an indication of the histological appearance, 68 specimens containing ACF or normal mucosa were examined histologically. The presence of slit-like lumen in the crypts of ACF on the mucosal surface correlated with the presence of dysplasia at histology, thus identifying microadenomas. These two observations suggest that the topographic classification of ACF in vivo could be used to distinguish microadenomas, a putative precursor lesion of colon cancer.

Entities:  

Mesh:

Year:  1991        PMID: 1845171

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  28 in total

1.  Identification of dysplasia in human colonic aberrant crypt foci.

Authors:  I M Siu; T G Pretlow; S B Amini; T P Pretlow
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Severe imbalance of cell proliferation and apoptosis in the left colon and in the rectosigmoid tract in subjects with a history of large adenomas.

Authors:  M Anti; A Armuzzi; S Morini; E Iascone; G Pignataro; C Coco; R Lorenzetti; M Paolucci; M Covino; A Gasbarrini; F Vecchio; G Gasbarrini
Journal:  Gut       Date:  2001-02       Impact factor: 23.059

Review 3.  Aberrant crypt foci in colorectal carcinogenesis. Cell and crypt dynamics.

Authors:  L Roncucci; M Pedroni; F Vaccina; P Benatti; L Marzona; A De Pol
Journal:  Cell Prolif       Date:  2000-02       Impact factor: 6.831

4.  Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2.

Authors:  Stella R Zamuner; Adrian W Bak; Pallavi R Devchand; John L Wallace
Journal:  Am J Pathol       Date:  2005-11       Impact factor: 4.307

5.  Aspirin, but not sodium salicylate, indomethacin, or nabumetone, reversibly suppresses 1,2-dimethylhydrazine-induced colonic aberrant crypt foci in rats.

Authors:  C J Barnes; W E Hardman; I L Cameron; M Lee
Journal:  Dig Dis Sci       Date:  1997-05       Impact factor: 3.199

6.  Two types of putative preneoplastic lesions identified by hexosaminidase activity in whole-mounts of colons from F344 rats treated with carcinogen.

Authors:  T P Pretlow; M A O'Riordan; K M Spancake; T G Pretlow
Journal:  Am J Pathol       Date:  1993-06       Impact factor: 4.307

7.  Proximal Aberrant Crypt Foci Associate with Synchronous Neoplasia and Are Primed for Neoplastic Progression.

Authors:  David A Drew; Allen Mo; James J Grady; Richard G Stevens; Joel B Levine; Bruce M Brenner; Joseph C Anderson; Faripour Forouhar; Michael J O'Brien; Thomas J Devers; Daniel W Rosenberg
Journal:  Mol Cancer Res       Date:  2017-12-08       Impact factor: 5.852

8.  Nuclear DNA content of isolated crypts of background colonic mucosa from patients with familial adenomatous polyposis and sporadic colorectal cancer.

Authors:  S Nakamura; I Kino; S Baba
Journal:  Gut       Date:  1993-09       Impact factor: 23.059

Review 9.  Aberrant crypt foci as microscopic precursors of colorectal cancer.

Authors:  Lei Cheng; Mao-De Lai
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

Review 10.  Aberrant crypt foci as precursors in colorectal cancer progression.

Authors:  Frank A Orlando; Dongfeng Tan; Juan D Baltodano; Thaer Khoury; John F Gibbs; Victor J Hassid; Bestoun H Ahmed; Sadir J Alrawi
Journal:  J Surg Oncol       Date:  2008-09-01       Impact factor: 3.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.